Navigation Links
Nutra Pharma CEO Interviewed by Wall Street Reporter
Date:10/28/2011

CORAL SPRINGS, Fla., Oct. 28, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, announced today that its Chief Executive Officer, Rik J. Deitsch, was interviewed by The Wall Street Reporter Senior Analyst Juan Costello. The interview provides an overview of the Company, its technology and an update on the Company's recent achievements. In addition, it provides a brief outlook of how Nutra Pharma views its business opportunities in the coming months.

"This interview has allowed us to provide some additional information on our two most recent press releases," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Recently, we announced the issuance of our newest patent that protects our drug technology for the treatment of Multiple Sclerosis. Additionally, we reported expanded international reach for our Nyloxin products through our new Distributor in Panama. The Company is now endeavoring to make it clear to the public that we have definitive short-term goals with the distribution of our drugs for the treatment of chronic pain; as well as long-term goals with our deep, drug discovery pipeline," he explained.

The interview is available on the Wall Street Reporter website under the "CEO Interviews" section and can be accessed directly via the link: http://tinyurl.com/NutraCEO

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The interview on The Wall Street Reporter should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
2. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
3. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
4. 2nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More
5. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
6. WellGen Recognized as Nutraceutical “Innovator” by Global Business Insights
7. Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications
8. Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health
9. Reuters Highlights NutraPharma Financial Giant Predicts NutraPharma (OTCBB: NPHC) Shares Likely to Outperform the Market
10. Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
11. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Diversity focused business accelerator, The ... Growth pitch competition to uncover the top technology-driven, women-led startups in Boston, MA, New ... of each city’s entrepreneurial events going on that week – in Boston, it will ...
(Date:9/20/2017)... Palo Alto, CA (PRWEB) , ... September 20, ... ... and public interest organization focused on molecular manufacturing and other transformative technologies, announced ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/19/2017)... ... , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured ... Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and ... in the potential of stem cell therapy and a fast friendship was formed. , Dr. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... today announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ ... image analysis to isolate single cells and provide visual documentation of monoclonality for ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):